Here’s our Fast Money Final Trade. Our gang gives you tomorrow’s best trades, right now.
Tim Seymour suggests longBarclay’s on the dip.
Guy Adami recommends long Human Genome (scroll down for all the details!)
Karen Finerman prefers long IBB as a bet on further consolidation in biotech.
Anthony Scaramucci thinks Hewlett Packard is a buy. “I think there are better quarters to come,” he explains.
Steve Cortes suggests long UNP. “I like the rails here,” he says.
AFTER HOURS ACTION: ZYMOGENETICS
After the bell, Bristol-Myers Squibb said it would acquire biotechnology company ZymoGenetics. for $885 million, or $9.75 per share a 77% premium over the closing price.
ZymoGenetics is based in Seattle and makes Recothrom, a drug used to reduce bleeding during surgeries. It is also developing a potential hepatitis C drug and experimental treatments for skin cancer and atopic dermatitis.
What’s the trade?
I’d play the space long Human Genome, says Guy Adami. I wouldn’t be surprised to hear Glaxo make overtures for this company.